Upadacitinib tartrate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Upadacitinib tartrate
- Molecular weight
- 602.52
- Structure (SMILES)
- CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12.O.O.O.O.O=C(O)C(O)C(O)C(=O)O
- abt 494 tartrate tetrahydrate
- ABT-494 TARTRATE TETRAHYDRATE
- upadacitinib tartrate
- Upadacitinib tartrate
- UPADACITINIB TARTRATE [USAN]
- upadacitinib tartrate tetrahydrate
- UPADACITINIB TARTRATE TETRAHYDRATE
- upadacitinib tartrate usan
- CAS registry numbers
- 1607431-21-9
- ChEMBL ID
- CHEMBL3707269
- InChIKey
- LATZVDXOTDYECD-UFTFXDLESA-N
- FDA ingredient codes (UNII)
- 7KCW9IQM02
- 122197532
- 127263217
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tinib
- Mechanism
- Tyrosine-protein kinase JAK1 inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase JAK1
- Mechanism
- Tyrosine-protein kinase JAK2 inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase JAK2
- Mechanism
- Tyrosine-protein kinase JAK3 inhibitor
- Action type
- Inhibitor
- Target
- Tyrosine-protein kinase JAK3
- Mechanism
- Tyrosine-protein kinase TYK2 inhibitor
- Action type
- Inhibitor
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Condition identifier
- EFO_0009856
- Highest recorded phase
- 2
- Condition identifier
- HP_0002094
- Highest recorded phase
- 3
- Condition identifier
- HP_0002098
- Highest recorded phase
- 3
- Condition identifier
- HP_0002360
- Highest recorded phase
- 3
- Condition identifier
- HP_0010447
- Highest recorded phase
- 1
- Condition identifier
- HP_0012378
- Highest recorded phase
- 3
- Condition identifier
- HP_0100543
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004980
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005083
- Condition identifier
- MONDO_0005101
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005265
- Condition identifier
- MONDO_0005306
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005340
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005361
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006559
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007191
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008383
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008538
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0008558
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008661
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0010030
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011429
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0011849
- Highest recorded phase
- 4
And 4 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- carcinogenicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- antibiotic therapy
- Reports
- 8
- Reporting signal score
- 25.0786
- Event
- covid-19
- Reports
- 110
- Reporting signal score
- 213.213
- Event
- herpes zoster
- Reports
- 66
- Reporting signal score
- 83.0762
- Event
- illness
- Reports
- 50
- Reporting signal score
- 107.373
- Event
- infected lymphocele
- Reports
- 5
- Reporting signal score
- 23.2141
- Event
- infection
- Reports
- 55
- Reporting signal score
- 32.1648
- Event
- localised infection
- Reports
- 24
- Reporting signal score
- 32.8098
- Event
- lumbosacral plexopathy
- Reports
- 6
- Reporting signal score
- 33.3652
- Event
- oral lichen planus
- Reports
- 7
- Reporting signal score
- 24.1549
- Event
- perineal rash
- Reports
- 6
- Reporting signal score
- 32.1383
- Event
- rheumatoid arthritis
- Reports
- 58
- Reporting signal score
- 42.0142
- Event
- sars-cov-2 test positive
- Reports
- 13
- Reporting signal score
- 26.5293
- Event
- sinusitis
- Reports
- 49
- Reporting signal score
- 37.1492
- Event
- therapy interrupted
- Reports
- 204
- Reporting signal score
- 699.51
- Event
- urinary tract infection
- Reports
- 92
- Reporting signal score
- 72.6318
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 2
- Polar surface area
- 78.32
- Calculated partition coefficient (ALogP)
- 2.91
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 41
- Molecular formula
- C21H33F3N6O11
- Monoisotopic mass
- 602.21594038
- Natural product
- No
Related records
Trials (114)
- A 24-Week Real-World Study of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa
- A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
- A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
- A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis
- A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
- A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
- A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
- A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
- A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
- A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
- A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone
- A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
- A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
- A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
- A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
- A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
- A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State